ASCL2 and colorectal carcinoma: Although independent analyses are needed, a KISIMA-Ascl2 vaccine may provide protection to individuals with Lynch syndrome who face a >50% lifetime risk of developing CRC and are in urgent need of safe, effective, and durable preventive therapies [5].